Clinical observation of botulinum toxin type A combined with recombinant human type ? collagen injection in the treatment of periocular wrinkles

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055452

Enrollment

Unknown

Registered

2022-01-10

Start date

2022-01-20

Completion date

Unknown

Last updated

2023-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:One side of the face is injected with human collagen type III, and the other side is injected with normal saline

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. According to the Lemperle Wrinkle Assessment grading scale, the wrinkles around the eyes are moderate to severe, with a score of >= 2; 2. Aged >18 years, no gender limit; 3. Informed consent to this study and signed the informed consent; 4. Subjects who have good compliance and can regularly participate in follow-up.

Exclusion criteria

Exclusion criteria: 1. Those who have received any facial filler, botulinum toxin injection, chemical peeling, or laser cosmetic treatment within the past 1 year; 2. Those who have received any plastic and cosmetic surgery around the eyes in the past 2 years; 3. Those who plan to undergo any facial medical aesthetic treatment during the study period; 4. Those who are pregnant, breastfeeding and preparing for pregnancy; 5. Those who are known to be allergic to botulinum toxin type A, albumin, milk or collagen; 6. Patients with scar constitution, skin around the eyes combined with various bacteria, fungi, viruses and other infections; 7. Patients with severe heart, brain, liver, kidney, lung, blood and other systemic diseases, patients with autoimmune diseases, immunodeficiency, and systemic muscle activity disorders; 8. Those who have any facial diseases that affect the evaluation of wrinkles around the eyes (combined with scars, eczema, dermatitis, etc.) or any other diseases that may be irritated or stimulated by invasive operations (such as vitiligo, lichen planus, flat warts, precancerous or malignant skin tumors, etc.); 9. Use of neuromuscular drugs (such as aminoglycosides, penicillins, quinine, calcium channel antagonists, etc.) during the study; 10. Those who cannot participate in regular follow-up visits; 11. Other investigators judged to be inappropriate for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Wrinkle score;	—

Secondary

Measure	Time frame
Overall cosmetic improvement score;	—

Countries

China

Contacts

Public ContactLai Dihui

Beijing Chuiyangliu Hospital

drlaidihui@163.com+86 18911587612

Outcome results